|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.10.24 - 15:24
|
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire EN)
|
|
|
Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company's abstract “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD)” has been selected for a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, California, held October 23 to 27....
|
|
|
01.10.24 - 07:03
|
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event (GlobeNewswire EN)
|
|
|
Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual Kidney Disease Key Opinion Leader (KOL) Event held September 30, 2024. The event focused on the standard of care and existing medical need, market development and dynamics in kidney disorders, as well as on key statistical considerations in kidney disease drug development, with special emphasis on diabetic kidney disease (DKD)....
|
|
|
|
|
|
|
|
|
22.07.24 - 09:55
|
Vivoryon mit Neuausrichtung: Aktie legt weiter zu – das ist geplant (Der Aktionaer)
|
|
|
Die Aktie des früheren Alzheimer-Hoffnungsträgers Vivoryon hat zuletzt erneut zulegen können. Das deutsche Biotech-Unternehmen arbeitet derzeit an einer strategischen Neuausrichtung. Zukünftig will man sich auf Nierenerkrankungen konzentrieren. Zuletzt hat Vivoryon ein Update zum voraussichtlichen klinischen Entwicklungsplan gegeben....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
